Skip to main content

Avoiding recurrence of infection and minimising autoimmunity-induced side effects

29 Oct 2024
Immune Regulation
  • Risks of side effects caused by dysregulated immune system in drug development
  • Potential risks of immune senescence and aging in patients
  • Risks and management of autoimmune diseases after immune checkpoint blockade (ICB) therapy
  • Risks and management of infection after CAR-T therapy for B cell malignancy
Industry Experts
Zengli Guo, Associate Director - AstraZeneca